Why the study?
Does atorvastatin improve hematologic parameters associated with cardiovascular risk in patients with hypercholesterolemia?
Does atorvastatin improve hematologic parameters associated with cardiovascular risk in patients with hypercholesterolemia?
Atorvastatin treatment for 24 weeks significantly reduces mean platelet volume and neutrophil-to-lymphocyte ratio in patients with hypercholesterolemia, suggesting potential antiplatelet and anti-inflammatory benefits.
Answers are grounded in this paper and cite their sources.
May suggest anti-inflammatory effects in hypercholesterolemia; hypothesis-generating and requires RCTs before practice change.
Hematologic parameters such as mean platelet volume (MPV), red cell distribution width (RDW), and neutrophil to lymphocyte (N/L) ratio are associated with increased cardiovascular risk. We investigated the effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. A total of 79 patients with hypercholesterolemia and 47 normocholesterolemic healthy participants were included. Patients with hypercholesterolemia received 10 to 80 mg/d atorvastatin during a 24-week period. Hematologic parameters were measured at baseline and after 6 months. Atorvastatin treatment produced a significant decrease in MPV levels (9.3 ± 1.3 vs 9.1 ± 1.2 fL, P = .008) and platelet count (259 ± 61 vs 248 ± 51 10(9)/L, P = .005). The N/L ratio decreased significantly after atorvastatin treatment from 2.9 ± 1.2 to 2.6 ± 1.1, (P = .014). The RDW and platelet distribution width levels were not different among the study groups, before and after treatment. Atorvastatin may beneficially reduce MPV levels and N/L ratio. This antiplatelet and anti-inflammatory effect of atorvastatin treatment could play a role in reducing cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Akın et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: